Pepticom

Company Overview

Snapshot

Founded in December 2011 by Immanuel Lerner, Anwar Rayan, and Amit Michaeli, Pepticom operates with 11–50 employees. The company has raised $14.2 million across four funding rounds from three investors. In January 2025, Pepticom completed its Series A1 funding round.

Business overview

Pepticom is a biotechnology company that leverages artificial intelligence to enhance peptide drug discovery. Its algorithmic platform integrates principles from economic and molecular mechanics to generate a broad spectrum of active molecules, aiming to increase success rates and reduce the time and cost associated with traditional lab-based discovery methods. The company's technology is designed to address complex targets by designing innovative peptides at atomic resolution, including linear, helical, and cyclic peptides, and incorporating D and non-natural amino acids. Pepticom serves the pharmaceuticals and biotechnology industries, with a focus on drug discovery and development, and is involved in various discovery projects with academic and industry partners.

Strategic signal

In March 2021, Pepticom established a spin-off company, PeptiCov, specifically to focus on developing treatments for the SARS-CoV-2 virus. This strategic move demonstrates Pepticom's agility in responding to global health crises and its ability to leverage its AI-driven peptide discovery platform for urgent medical needs, signaling potential for rapid therapeutic development in critical areas.

Company Intelligence Q&A

What is Pepticom's core technology?

Pepticom utilizes an artificial intelligence-driven algorithmic platform that combines economic and molecular mechanics principles to design novel peptide drug candidates at atomic resolution, aiming to streamline drug discovery and address complex biological targets.

When was Pepticom founded and by whom?

Pepticom was founded in December 2011 by Immanuel Lerner, Anwar Rayan, and Amit Michaeli.

What significant funding event occurred in January 2025?

In January 2025, Pepticom announced the successful completion of its Series A1 funding round. The Chartered Group participated in this round.

What was the strategic focus of Pepticom's spin-off company, PeptiCov?

In March 2021, Pepticom established PeptiCov as a spin-off company dedicated to developing treatments for the SARS-CoV-2 virus responsible for the COVID-19 outbreak.

Which investor has frequently participated in Pepticom's funding rounds?

The Chartered Group has participated in multiple funding rounds for Pepticom, including the Series A1 round in January 2025 and a funding round in March 2021.